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Although the DSM-5 and the ICSD-3 do not discriminate 
among insomnia types or subtypes anymore, it appears 
that some specific insomnia phenotypes remain important 
to study. One of them is the object of the present paper: 
insomnia with short sleep duration. Since Vgontzas and 
colleagues (1) put forward a heuristic model of two insomnia 
phenotypes based on objective sleep duration, they have 
suggested that insomnia with short sleep duration is the 
most severe biological phenotype of insomnia, and research 
in this area has been blooming. The Penn State group 
has studied the impact of this phenotype on adolescents 
and its association with depression risks and inflammation 
(2-4). A recent review by Fernandez-Mandoza (5) also 
suggested that besides increased physiological hyperarousal 
and cardiometabolic and neuropsychiatric risks, insomnia 
with short sleep duration may even respond differently to 
treatment compared to other insomnia phenotypes. 
Cognitive Behavioural Therapy for Insomnia (CBT-I) 
has been used in numerous studies and its long-term 
efficacy has been recognized (6-9). CBT-I is the treatment 
of choice for insomnia (10). Despite this, since insomnia 
with short sleep duration is associated with physiological 
arousal, perhaps patients with this condition would benefit 
more from pharmacotherapy than CBT-I. 
It is unknown whether individuals with insomnia 
presenting with short sleep duration respond differently to 
CBT-I than those presenting with more normative sleep 
duration. This is precisely what Bathgate, Edinger and 
Krystal (11) aimed to study. From data collected as part 
of another study, they systemically divided 60 individuals 
suffering from insomnia (DSM-IV criteria) into two groups 
according to their sleep duration: short (less than 6 hours, 
N=30) and normal (6 hours and more; N=30) based on 
actigraphy (PSG data being unavailable). Once groups 
were aggregated, they received CBT-I treatment (1, 2, 
4 or 8 sessions). CBT-I mainly addressed dysfunctional 
beliefs and attitudes and behavioral strategies (stimulus 
control). Pre and post measures as well as 6 months follow-
up data were obtained using questionnaires, sleep diaries, 
and actigraphy. The results were in line with previous 
hypotheses: individuals suffering of insomnia and sleeping 
6 hours or less, according to actigraphy data, were less likely 
to be responsive to CBT-I than those sleeping more than 
6 hours; additionally, this effect persisted through follow-
up. Thus, insomnia coupled with short-sleep duration might 
be one of the phenotypes which presents more challenges 
when treated with CBT-I. Since the individuals of the 
study were all ‘pure’ insomnia sufferers, no other disorders 
could be linked to the limited responsiveness of individuals 
to the most common non-pharmacological treatment for 
insomnia: CBT-I. 
The results from Bathgate et al. provide one more 
reason, besides lack of adherence or challenging disorders, 
why some individuals do not respond well to treatment. 
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Whilst the seminal study by Ong, Kuo and Manber (12) 
does suggest a drop-out rate between 0% and 8% within 
the context of two RCTs, they also point to drop out rates 
ranging from 9.7% to 38.3% in clinical settings. Further, 
in their own analysis, 39.96% of subjects dropped out. 
These high levels are especially seen in clinical settings (12). 
Maybe these drop-out rates included short sleep duration 
insomnia patients. The question now is: What do we do 
with insomnia patients presenting with short sleep? Do 
we still consider them for CBT-I or would they benefit 
more from pharmacotherapy? Or would a modification to 
CBT-I be required? Of note, neither CBT-I nor insomnia 
pharmacotherapy have shown a consistent ability to increase 
sleep duration.
Future research should examine treatment approaches 
in this group of insomnia patients. For example, a 
study could verify whether these limitations are also 
seen with pharmacotherapy or with combined therapy 
(pharmacotherapy and CBT-I). Because individuals 
suffering from insomnia and presenting with a short-
sleep duration show increased health risks compared to 
individuals suffering from insomnia and sleeping 6 hours 
and more, it should be a priority to find a beneficial 
treatment for these short-sleepers. In addition, if insomnia 
with short-sleep duration is biologically determined, its 
neurobiological underpinnings should be studied so to 
adapt treatment to this population. Meanwhile, in current 
CBT-I trials, it might be advisable to take into account 
baseline sleep duration when treatment efficacy is the main 
outcome.
Curiously, Bathgate et al. claimed that CBT-I is not 
efficacious for those suffering sleep-state misperception 
(i.e., paradoxical insomnia). To our knowledge, there are 
few studies examining treatment specifically among patients 
with this condition. One study by the Lichstein group (13), 
although limited by the number of participants, did show 
that individuals suffering from paradoxical insomnia, when 
confronted to their own PSG data, more readily accept the 
fact they are grossly misestimating their sleep. In addition, 
personally addressing PSG data decreases hyperarousal 
linked to misperception and then, insomnia patients may 
be more receptive to CBT-I. It is not clear if the allusion 
to the lack of effectiveness of CBT-I treatment in the 
Bathgate et al. (11) paper refers to clinical data (from 
practice) or published research; perhaps it simply reflects 
a lack of efficacy data. Misperception of sleep is quite a 
challenge and its underlying mechanisms remain poorly 
studied (14). Still, cognitive therapy, which by definition 
decreases emotional arousal and cognitive arousal (this 
latter being itself linked to cortical arousal) might plausibly 
be effective in diminishing sleep misperception. Bathgate 
et al. suggest that this is not the case, despite a sufficient 
justification for this claim. It is also still unknown the extent 
to which sleep misperception contributes to the limited 
effectiveness of CBT-I in general clinical trials. Paradoxical 
insomnia, to some extent, thus also appears as a phenotype 
unresponsive to CBT-I according to Bathgate et al. It would 
be interesting to develop a protocol taking into account 
both phenotypes. More research should be devoted to 
also understanding the misperception of sleep as it may be 
one of the limitation of the efficacy of current insomnia 
treatments. 
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